Related Experiment Video

Updated: Jun 27, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

A substrate peptide for the FLT3 receptor tyrosine kinase

Frank-D Böhmer1, Andrea Uecker

  • 1Institute of Molecular Cell Biology, Centre for Molecular Biomedicine, Friedrich Schiller University, Jena, Germany. boehmer@med.uni-jena.de

British Journal of Haematology
|November 20, 2008
PubMed

Insights

Researchers identified a novel peptide substrate for fms-like tyrosine kinase 3 (FLT3) phosphorylation. This peptide aids in the development and characterization of FLT3 inhibitors for acute myeloid leukemia treatment.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Fms-like tyrosine kinase 3 (FLT3) mutations are common in acute myeloid leukemia (AML).
  • FLT3 is a significant drug target for AML therapy.
  • Efficient peptide substrates are crucial for evaluating tyrosine kinase inhibitors.

Purpose of the Study:

  • To identify and characterize novel peptide substrates for FLT3.
  • To develop a tool for testing FLT3 kinase inhibitors.

Main Methods:

  • Phosphorylation experiments were conducted on peptide arrays.
  • In-solution phosphorylation assays were performed.
  • Kinetic parameters, including apparent Km, were determined.

Main Results:

  • A specific peptide, F-T-D-R-L-Q-Q-Y(8)-I-S-T-R-G-L-G, was found to be efficiently phosphorylated by FLT3.
  • The apparent Km for this substrate was determined to be 10 micromol/l.
  • Tyrosine 8 (Y8) was identified as the primary phosphorylation site.

Conclusions:

  • The identified peptide is a novel and efficient substrate for FLT3.
  • This peptide serves as a valuable tool for the identification and characterization of FLT3 inhibitors.
  • This research facilitates the development of targeted therapies for AML.

More Related Videos

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

Related Concept Videos

Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...